Company / EPS (Diluted)
Outlook Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.06
FY2025
5-year range
-$9.74 / -$1.80
FY2021-FY2025
Trend
-105.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 6 years, ranging from $-9.74 in FY2019 to $-1.80 in FY2018.
Based on SEC 10-K filings.
-4.06 in FY2025.
Improved from $-9.74 to $-4.06 over the past 6 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 105.1% year-over-year.
- Peak eps (diluted) was recorded in FY2018.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.06 | -105.1% |
| FY2020 | -$1.98 | +79.7% |
| FY2019 | -$9.74 | -441.1% |
| FY2018 | -$1.80 | +51.0% |
| FY2017 | -$3.67 | +32.4% |
| FY2016 | -$5.43 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026